- Home
- TFC vs TAK Comparison
TFC vs TAK Comparison
Compare TFC & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TFC | TAK |
|---|---|---|
| Founded | 1872 | 1781 |
| Country | United States | Japan |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.4B | 55.5B |
| IPO Year | 2007 | 2007 |
Fundamental Metrics
Financial Performance| Metric | TFC | TAK |
|---|---|---|
| Price | $50.79 | $18.25 |
| Analyst Decision | Buy | |
| Analyst Count | 14 | 0 |
| Target Price | ★ $54.11 | N/A |
| AVG Volume (30 Days) | ★ 5.9M | 3.3M |
| Earning Date | 04-17-2026 | 05-13-2026 |
| Dividend Yield | ★ 4.11% | 3.24% |
| EPS Growth | ★ 13.69 | N/A |
| EPS | ★ 2.31 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.27 | $0.16 |
| Revenue Next Year | $4.48 | $1.22 |
| P/E Ratio | ★ $21.78 | $41.25 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $40.79 | $12.99 |
| 52 Week High | $56.20 | $18.90 |
Technical Indicators
Market Signals| Indicator | TFC | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 42.04 | 65.86 |
| Support Level | $48.26 | $17.40 |
| Resistance Level | $51.02 | $18.51 |
| Average True Range (ATR) | 0.79 | 0.18 |
| MACD | -0.30 | 0.06 |
| Stochastic Oscillator | 12.99 | 86.42 |
Price Performance
Historical ComparisonAbout TFC Truist Financial Corporation
Truist Financial is one of the three super-regional banks in the US, with around $550 billion in assets as of the first quarter of 2026. Truist emerged from the combination of BB&T and SunTrust in 2019. Based in Charlotte, North Carolina, the bank's footprint is largely in the Mid-Atlantic and Southeast. Apart from retail and commercial banking operations, the bank also offers online and point-of-sale consumer lending, cards, wealth management, investment banking, and other banking services.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.